{
  "symbol": "MRK",
  "year": 2024,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2441,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.051
  },
  "top_positive": [
    {
      "sent": "Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended March\u00a031, 2024 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) January 1 - January 31 147,500 $112.29 147,500 $3,684 February 1 - February 29 209,200 $127.83 209,200 $3,658 March 1 - March 31 633,971 $123.45 633,971 $3,579 Total 990,671 $122.71 990,671 (1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck\u2019s common stock for its treasury.",
      "score": 0.968
    },
    {
      "sent": "Restructuring In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company\u2019s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.",
      "score": 0.936
    },
    {
      "sent": "Restructuring Costs In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company\u2019s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.",
      "score": 0.936
    }
  ],
  "top_negative": [
    {
      "sent": "Phase 2 Cancer MK-1022 (patritumab deruxtecan) (1) Gastric Melanoma MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Colorectal MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) (1) Colorectal Small-Cell Lung MK-2870 (sacituzumab tirumotecan) (1)(3) Neoplasm Malignant MK-3475 Keytruda Advanced Solid Tumors Prostate MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Cutaneous Squamous Cell MK-4280 (favezelimab) (2) Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Bladder Cutaneous Squamous Cell Endometrial Esophageal Melanoma Renal Cell MK-5890 (boserolimab) (2) Neoplasm Malignant Cancer MK-5909 (raludotatug deruxtecan) (1) Ovarian MK-6482 Welireg (3) Endometrial Esophageal Hepatocellular Prostate Rare cancers MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684A (vibostolimab+pembrolizumab) Biliary Bladder Breast Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hepatocellular Ovarian Prostate Renal V940 (1)(2) Cutaneous Squamous Cell Bladder Renal Cell Cancer MK-7902 Lenvima (1)(2) Head and Neck Dengue Fever Virus Vaccine V181 HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(5) HIV-1 Prevention MK-8527 Nonalcoholic Steatohepatitis (NASH) MK-6024 (efinopegdutide) Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 Winrevair Schizophrenia MK-8189 (6) Thrombosis MK-2060 Vitiligo MK-6194 - 36 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(7) Cancer MK-1022 (patritumab deruxtecan) (1) Non-Small-Cell Lung (May 2022) (EU) MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-2870 (sacituzumab tirumotecan) (1)(3) Breast (April 2024) Endometrial (December 2023) Non-Small-Cell Lung (November 2023) MK-3475 Keytruda Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-3543 (bomedemstat) Myeloproliferative Disorders (December 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-5684 (opevesostat) (1) Prostate (December 2023) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Melanoma (January 2023) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Esophageal (July 2021) Gastric (December 2020) V940 (1)(2) Melanoma (July 2023) Non-Small-Cell Lung (December 2023) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (5) Hypercholesterolemia MK-0616 (August 2023) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) Ulcerative Colitis MK-7240 (tulisokibart) (October 2023) New Molecular Entities Ca ncer MK-1022 (patritumab deruxtecan) (1) Non-Small-Cell Lung (U.S.) MK-6482 Welireg Von Hippel-Lindau (VHL) Disease (EU) Cough MK-7264 (gefapixant) (U.S.) (8) Pneumococcal Vaccine Adult V116 (U.S.) (EU) Pulmonary Arterial Hypertension MK-7962 Winrevair (EU) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Primary Advanced or Recurrent Endometrial Carcinoma (KEYNOTE-868) (U.S.) (EU) (JPN) \u2022    First-Line Locally Advanced or Metastatic Urothelial Cancer (KEYNOTE-A39) (EU) (JPN) \u2022    High-Risk Locally Advanced Cervical Cancer (KEYNOTE-A18) (EU) (JPN) \u2022    Resectable Stage II, IIIA or IIIB NSCLC (KEYNOTE-671) (JPN) \u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KEYNOTE-859) (JPN) \u2022    First-Line Locally Advanced Unresectable or Metastatic Biliary Tract Cancer (KEYNOTE-966) (JPN) MK-6482 Welireg \u2022    Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-005) (EU) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.9861
    },
    {
      "sent": "\u2014 1,192 Deferred income taxes ( 51 ) ( 277 ) Share-based compensation 176 145 Other 83 ( 197 ) Net changes in assets and liabilities ( 3,382 ) ( 2,890 ) Net Cash Provided by Operating Activities 3,090 1,339 Cash Flows from Investing Activities Capital expenditures ( 861 ) ( 1,007 ) Purchases of securities and other investments ( 15 ) ( 562 ) Proceeds from sales of securities and other investments 260 500 Acquisition of Harpoon Therapeutics, Inc., net of cash acquired ( 746 ) \u2014 Acquisition of Imago BioSciences, Inc., net of cash acquired \u2014 ( 1,327 ) Other ( 14 ) 37 Net Cash Used in Investing Activities ( 1,376 ) ( 2,359 ) Cash Flows from Financing Activities Payments on debt ( 751 ) ( 1 ) Dividends paid to stockholders ( 1,950 ) ( 1,853 ) Purchases of treasury stock ( 122 ) ( 149 ) Proceeds from exercise of stock options 87 30 Other ( 78 ) ( 81 ) Net Cash Used in Financing Activities ( 2,814 ) ( 2,054 ) Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash ( 138 ) 87 Net Decrease in Cash, Cash Equivalents and Restricted Cash ( 1,238 ) ( 2,987 ) Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $ 68 and $ 79 at January 1, 2024 and 2023, respectively, included in Other current assets ) 6,909 12,773 Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $ 92 and $ 79 at March\u00a031, 2024 and 2023, respectively, included in Other current assets ) $ 5,671 $ 9,786 The accompanying notes are an integral part of this condensed consolidated financial statement.",
      "score": -0.7003
    },
    {
      "sent": "The Biologics License Application (BLA) is based on the primary results from the HERTHENA-Lung01 pivotal Phase 2 trial and data results presented at the IASLC 2023 World Conference on Lung Cancer, which were simultaneously published in the Journal of Clinical Oncology.",
      "score": -0.6597
    }
  ],
  "forward_snippets": [
    "Recently Issued Accounting Standards Not Yet Adopted In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation.",
    "The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance.",
    "The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively.",
    "In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses.",
    "The guidance is effective for annual periods beginning in 2024, and interim periods beginning in 2025."
  ]
}